Manage your personalised Watchlist.Set up an online Virtual Portfolio.Participate in Share Chat.See more trades and director dealings.Play the Fantasy Share Trading Game.
Surface Transforms management deliver positive operational update 16.09.2019 Watch Now
Posted in: SKIN
They don't have labskin
Posted in: NFX
When I first invested there was a strong indication that the company was actively seeking licensing agreements for 001 in other parts of the world including Australia. What has happened to these activities?
No...afraid I'm old and unable to do long journeys.
According to the Company's website...investor relations....the agm will.be used to communicate with shareholders...Well?
Surely Venn shares still being sold by those who 'helped out' when broker arranged deal in 5 minutes
The silence from BoD is deafening
There is no broker yet
When you do business internationally you have to take account of political risk.
But I'm sure they will be actively networking on the 4th
The presence of Labskin ai at the conference could have stirred interest from the U S especially as the shares are still very cheap
What is going on politically between China and the UK is scary.
Still a seller out there 1.5 million sold this morning
GB on holiday I believe
Ha! Rescued it. The money comes from the Engineering and Physical Sciences Research Council
Sorry...my son destroyed the paper. I do recollect that the engineers want to look at the mechanics of the healing process so maybe unrelated to our product
See article in today's I newspaper page 5. Engineers at Heriot-Watt University are being given money to develop a micro sensor that can monitor healing wounds. They don't know about our product!
Sorry should have reported back. Been busy. He did reply and said that with Stoer and the wound product he felt the category is correct at the moment.
The problem is that shareholders have been kept short of information for too long. For a main listed share this is not good enough
Thank you. I have emailed him. I just think it is misleading.